Evoke Pharma (NASDAQ:EVOK) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research report sent to investors on Tuesday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Trading Down 2.4 %

Shares of NASDAQ:EVOK opened at $4.41 on Tuesday. The company has a market capitalization of $6.57 million, a price-to-earnings ratio of -0.40 and a beta of 0.16. Evoke Pharma has a 12-month low of $3.54 and a 12-month high of $12.84. The business has a 50-day moving average price of $4.69 and a 200 day moving average price of $5.14.

Institutional Investors Weigh In On Evoke Pharma

A hedge fund recently bought a new stake in Evoke Pharma stock. Corsair Capital Management L.P. acquired a new stake in Evoke Pharma, Inc. (NASDAQ:EVOK) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned approximately 1.42% of Evoke Pharma as of its most recent filing with the Securities & Exchange Commission.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.